Ellen J. Kim, MD
Professor of Dermatology at the Hospital of the University of Pennsylvania
Attending Physician, Abramson Cancer Center, Hospital of the University of Pennsylvania
Director, Penn Cutaneous Lymphoma Program, Department of Dermatology, Hospital of the University of Pennsylvania
Vice Chair, Clinical Operations, Department of Dermatology, Hospital of the University of Pennsylvania
Department: Dermatology
Contact information
Department of Dermatology
Perelman School of Medicine at the University of Pennsylvania
Room 721, 7th Floor - South Tower
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman School of Medicine at the University of Pennsylvania
Room 721, 7th Floor - South Tower
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-2737
Fax: 215-615-4966
Fax: 215-615-4966
Education:
A.B. (East Asian Studies)
Harvard University, 1991.
M.D.
University of Pennsylvania, 1996.
Permanent linkA.B. (East Asian Studies)
Harvard University, 1991.
M.D.
University of Pennsylvania, 1996.
Description of Research Expertise
Clinical trials for cutaneous T-cell lymphoma (CTCL)Description of Clinical Expertise
Cutaneous Lymphomas (T-cell and B-cell) and lymphoproliferative disordersGraft vs Host Disease
Extracorporeal Photopheresis
Selected Publications
Asare C, Raymundo C, Chen J, Perez-Chada L, Tawa M, Thornton S, Ottevanger R, Scarisbrick J, Olsen E, Khan N, Kim EJ, Shinohara MM, Larocca C;: International Dermatology Outcomes Measures Cutaneous Lymphoma Working Group Additional Members: Neha Mehta Shah, Jenny Park, Krithika Nayudu. Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials. BMJ Open 16(2): e103498, Feb 2026.Cohen LS, Adeuyan O, Margolis DJ, Kim EJ, Chung J. : Medicare coverage of home phototherapy units for cutaneous T-cell lymphoma versus psoriasis. J Am Acad Dermatol 94(2): 693-695, Feb 2026.
Rastogi S, Brown-Korsah J, Kim EJ: Cutaneous T-cell Lymphoma. Taylor and Kelly's Dermatology for Skin of Color, 3rd Edition textbook Susan C. Taylor, MD and Henry Lim, MD (eds.). McGraw Hill, 2026.
Willemze R, Assaf C, Bagot M, Beylot-Barry M, Berti E, Busschots AM, Cerroni L, Climent F, Diercks G, Geskin L, Gniadecki R, Gru AA, Guenova E, Guitart J, Jansen P, Kempf W, Kim E, Kim YH, Koldijk M, Marschalkó M, Mitteldorf C, Molgó M, Muniesa C, KJ Neelis, Olsen E, Ortiz-Romer PLo, Papadavid E, Pimpinelli N, Pulitzer M, Quaglino P, Querfeld C, Quint K, Scarisbrick JS, Schrader AMR, Stadler R, Vermeer M, Wehkamp U, Whittaker S, Wobser M.: European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. Br J Dermatol 193(6): 1090-1100, Dec 2025.
Kossenkov AV, Dawany N, Majumdar S, Chang C, Nichols C, Wysocka M, Piekarz R, Showe MK, Bates SE, Rook AH, Kim EJ, Showe LC. : Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment. Cancers 17(14): 2380, Jul 2025.
Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM.: Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study. Journal of the American Academy of Dermatology 2025-05-01. J Am Acad Dermatol. 92(5): 1100-1102, May 2025.
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 92(3): 634-636, Mar 2025.
Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol 161(6): 656-658, 2025.
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol Nov 2024 Notes: doi: 10.1016/j.jaad.2024.10.095.
Villasenor-Park J, Chung J, Kim EJ: Cutaneous B-cell Lymphomas/Cutaneous Oncology. Hematology Oncology Clinics. Fisher D (eds.). Elsevier, 38(5): 1111, October 2024.